Stock IMM IMMUTEP LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Immutep Limited

Equities

IMM

AU000000IMM6

Market Closed - Australian S.E.
Other stock markets
 02:10:55 2024-04-23 am EDT 		5-day change 1st Jan Change
0.385 AUD +8.45% Intraday chart for Immutep Limited +6.94% +11.59%
Apr. 18 Immutep Limited Appoints Leading Research Institute to Conduct First-In-Human Phase I Study of IMP761 CI
Apr. 18 Immutep Taps Center for Human Drug Research for IMP761 Human Clinical Trial MT

Evolution of the average Target Price on Immutep Limited

Price target over the last 5 years

History of analyst recommendation changes

5e.oQmkbzl4SiguC-QXHGdTt_C4IjEBZ0fwAwF0DPMbFgM.mFydMG42KWV_X7taSCRkzYWMb1wsVi-4enlDQb1vV3nzU8YLdyguYUtpsQ~049be60f19b53730b6c56d9def805233

Analyst Recommendations on Immutep Limited

Baird Initiates Immutep With Outperform Rating, $7 Price Target MT
Maxim Group Adjusts Price Target on Immutep to $10 From $8, Keeps Buy Rating MT
Immutep Limited Reports Positive Overall Response Rate in Its Phase II Clinical Trial in 1st line NSCLC for PD-L1 All-Comers CI
AIPAC final data as expected: Phase III supported with maintaining a Buy Rating (ASX:IMM) (Analysts: Dr Melissa Benson and Dr Shane Storey) PU
O/W: IMMune to failure - Initiating coverage with a Buy Rating (ASX:IMM) (Analysts: Dr Melissa Benson and Dr Shane Storey) PU
Immutep : Ladenburg Thalman - New Age Immune Regulator; Initiate with a Buy Rating and $8.30 Price Target PU
IMMUTEP : Ladenburg Thalmann Starts Immutep at Buy With $8.30 Price Target MT
Immutep : Maxim Group - Unlocking the Synergistic Benefits of Efti (LAG-3), the Next Checkpoint - Transferring Coverage with a Buy Rating and $8 PT PU
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.355 AUD
Average target price
0.9 AUD
Spread / Average Target
+153.52%
High Price Target
1.1 AUD
Spread / Highest target
+209.86%
Low Price Target
0.65 AUD
Spread / Lowest Target
+83.10%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Immutep Limited

Baird
Maxim
Ladenburg Thalmann

Ratings for Immutep Limited

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. IMM Stock
  4. Consensus Immutep Limited